This product is a recombinant mouse antibody that recognizes human CD44. CD44 is a cell surface antigen that expresses on leukemia blasts from most acute myeloid leukemia (AML) patients. Mab HI44a effectively induces both differentiation and apoptosis of AML cells and suggest that this activity of the anti-CD44 antibody may be associated with its inhibitory effect on c-myc transcript expression. This antibody can be used in the treatment of leukemia.
Figure 1 Modulation of nitroblue tetrazolium (NBT)-reducing ability of different types of acute myeloid leukemia cells by HI44a, a monoclonal antibody against CD44.
Leukemia cells were incubated with HI44a at 10-50 μg/ml. The percentage of NBT+ cells was evaluated. Results are shown as the mean (±S.D.) of specific subtype cases.
Song, G., Liao, X., Zhou, L., Wu, L., Feng, Y., & Han, Z. C. (2004). HI44a, an anti-CD44 monoclonal antibody, induces differentiation and apoptosis of human acute myeloid leukemia cells. Leukemia research, 28(10), 1089-1096.
Figure 2 HI44a-induced differentiation of AML-M2 to AML-M5 leukemia cells.
Cells were incubated with 10-50 μg/ml HI44a. Treated cells and controls were stained with PE-conjugated anti-CD11b monoclonal antibody and FITC-conjugated anti-CD14 (monocyte-specific) or anti-CD15 (granulocyte-specific) monoclonal antibody. The %CD11b+, CD14+, or CD15+ cells was determined by flow cytometry. (a) Simultaneous increased expression of CD11b and CD14; (b) increased expression of CD15.
Song, G., Liao, X., Zhou, L., Wu, L., Feng, Y., & Han, Z. C. (2004). HI44a, an anti-CD44 monoclonal antibody, induces differentiation and apoptosis of human acute myeloid leukemia cells. Leukemia research, 28(10), 1089-1096.
Figure 3 HI44a induced change of cytological features in AML-M3 and AML-M5 cells.
Song, G., Liao, X., Zhou, L., Wu, L., Feng, Y., & Han, Z. C. (2004). HI44a, an anti-CD44 monoclonal antibody, induces differentiation and apoptosis of human acute myeloid leukemia cells. Leukemia research, 28(10), 1089-1096.
Figure 4 FITC-annexin-V evaluation of early apoptotic cells. Early apoptotic cells are FITC-positive and PI-negative.
Song, G., Liao, X., Zhou, L., Wu, L., Feng, Y., & Han, Z. C. (2004). HI44a, an anti-CD44 monoclonal antibody, induces differentiation and apoptosis of human acute myeloid leukemia cells. Leukemia research, 28(10), 1089-1096.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-727 | Anti-CD44 Recombinant Antibody (Bivatuzumab) | ELISA, FC, IP, FuncS, IF, Neut, ICC | IgG1 |
TAB-236LC | Anti-Human CD44 Recombinant Antibody (huPTA-4621) | FuncS | Humanized antibody |
TAB-236LC-S(P) | Anti-Human CD44 Recombinant Antibody scFv Fragment (huPTA-4621) | FC | Humanized antibody |
TAB-236LC-F(E) | Anti-Human CD44 Recombinant Antibody Fab Fragment (huPTA-4621) | FC | Humanized antibody |
There are currently no Customer reviews or questions for HPAB-0047-YJ. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.